Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial
•A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus g...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2017-10, Vol.35 (43), p.5897-5904 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5904 |
|---|---|
| container_issue | 43 |
| container_start_page | 5897 |
| container_title | Vaccine |
| container_volume | 35 |
| creator | Mo, Zhaojun Mo, Yi Li, Mingqiang Tao, Junhui Yang, Xu Kong, Jilian Wei, Dingkai Fu, Botao Liao, Xueyan Chu, Jianli Qiu, Yuanzheng Hille, Darcy A. Nelson, Micki Kaplan, Susan S. |
| description | •A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus gastroenteritis caused by any serotype was 78.9%.•RV5 was efficacious and generally well-tolerated in Chinese infants.
A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE).
4040 participants aged 6–12weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n=2020) or placebo (n=2020), administered ∼4weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14days after the third dose. All adverse events (AEs) were collected for 30days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385).
VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related.
In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs. |
| doi_str_mv | 10.1016/j.vaccine.2017.08.081 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1942678514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X17311817</els_id><sourcerecordid>1942678514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-5224a1f65e01787d340b7f41055691a6d0ec1f9342a075a4a0a8abde7f5d33a63</originalsourceid><addsrcrecordid>eNqFkc-KFDEQxoMo7rj6CErAywr2mHQ6_Wcvsgy7KiwIouItVCcVJkO6MybdDeMr-ZKbYUYPXoSCIpVf1Vd8RchLztac8frdbr2A1m7Edcl4s2ZtDv6IrHjbiKKUvH1MVqysq6Li7McFeZbSjjEmBe-ekouy7YSsGrYiv2-tdRr0gcJoaAKL04EGS4HucZxgAZ8T9W5Bup0HGIs-LFmURoSUQpwg_8aQQRfnRM8r0asv3-Ub6ka6RfDT9kA321xOmEs2d6RrekNjFgyD-4XmLTVh7j0WvXdjfu09aOxDocM4xeA9GjpFB_45eWLBJ3xxzpfk293t183H4v7zh0-bm_tCi05MhSzLCritJWZj2saIivWNzTZIWXccasNQc9uJqgTWSKiAQQu9wcZKIwTU4pJcnebuY_g5Y5rU4JJG72HEMCfFu6qsm1byKqOv_0F3YY5j3u5ICZbJimdKnigdQ0oRrdpHN0A8KM7U8Zpqp87WqeM1FWtzHPtenafP_YDmb9ef82Xg_QnAbMfiMKqkHY4ajYuoJ2WC-4_EAwfEtO4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1943094241</pqid></control><display><type>article</type><title>Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial</title><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Mo, Zhaojun ; Mo, Yi ; Li, Mingqiang ; Tao, Junhui ; Yang, Xu ; Kong, Jilian ; Wei, Dingkai ; Fu, Botao ; Liao, Xueyan ; Chu, Jianli ; Qiu, Yuanzheng ; Hille, Darcy A. ; Nelson, Micki ; Kaplan, Susan S.</creator><creatorcontrib>Mo, Zhaojun ; Mo, Yi ; Li, Mingqiang ; Tao, Junhui ; Yang, Xu ; Kong, Jilian ; Wei, Dingkai ; Fu, Botao ; Liao, Xueyan ; Chu, Jianli ; Qiu, Yuanzheng ; Hille, Darcy A. ; Nelson, Micki ; Kaplan, Susan S.</creatorcontrib><description>•A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus gastroenteritis caused by any serotype was 78.9%.•RV5 was efficacious and generally well-tolerated in Chinese infants.
A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE).
4040 participants aged 6–12weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n=2020) or placebo (n=2020), administered ∼4weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14days after the third dose. All adverse events (AEs) were collected for 30days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385).
VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related.
In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2017.08.081</identifier><identifier>PMID: 28935470</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Antigens ; Diarrhea ; Disease control ; Disease prevention ; Double-blind studies ; Effectiveness ; Efficacy ; Gastroenteritis ; Guardians ; Hospitalization ; Immunization ; Infants ; Intussusception ; Pediatrics ; Randomization ; Rotavirus ; Rotavirus gastroenteritis ; Rotavirus vaccine ; Safety ; Serotypes ; Surveillance ; Vaccination ; Vaccine efficacy ; Vaccines ; Viruses</subject><ispartof>Vaccine, 2017-10, Vol.35 (43), p.5897-5904</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Oct 13, 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-5224a1f65e01787d340b7f41055691a6d0ec1f9342a075a4a0a8abde7f5d33a63</citedby><cites>FETCH-LOGICAL-c393t-5224a1f65e01787d340b7f41055691a6d0ec1f9342a075a4a0a8abde7f5d33a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1943094241?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28935470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mo, Zhaojun</creatorcontrib><creatorcontrib>Mo, Yi</creatorcontrib><creatorcontrib>Li, Mingqiang</creatorcontrib><creatorcontrib>Tao, Junhui</creatorcontrib><creatorcontrib>Yang, Xu</creatorcontrib><creatorcontrib>Kong, Jilian</creatorcontrib><creatorcontrib>Wei, Dingkai</creatorcontrib><creatorcontrib>Fu, Botao</creatorcontrib><creatorcontrib>Liao, Xueyan</creatorcontrib><creatorcontrib>Chu, Jianli</creatorcontrib><creatorcontrib>Qiu, Yuanzheng</creatorcontrib><creatorcontrib>Hille, Darcy A.</creatorcontrib><creatorcontrib>Nelson, Micki</creatorcontrib><creatorcontrib>Kaplan, Susan S.</creatorcontrib><title>Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus gastroenteritis caused by any serotype was 78.9%.•RV5 was efficacious and generally well-tolerated in Chinese infants.
A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE).
4040 participants aged 6–12weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n=2020) or placebo (n=2020), administered ∼4weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14days after the third dose. All adverse events (AEs) were collected for 30days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385).
VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related.
In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs.</description><subject>Age</subject><subject>Antigens</subject><subject>Diarrhea</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Double-blind studies</subject><subject>Effectiveness</subject><subject>Efficacy</subject><subject>Gastroenteritis</subject><subject>Guardians</subject><subject>Hospitalization</subject><subject>Immunization</subject><subject>Infants</subject><subject>Intussusception</subject><subject>Pediatrics</subject><subject>Randomization</subject><subject>Rotavirus</subject><subject>Rotavirus gastroenteritis</subject><subject>Rotavirus vaccine</subject><subject>Safety</subject><subject>Serotypes</subject><subject>Surveillance</subject><subject>Vaccination</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc-KFDEQxoMo7rj6CErAywr2mHQ6_Wcvsgy7KiwIouItVCcVJkO6MybdDeMr-ZKbYUYPXoSCIpVf1Vd8RchLztac8frdbr2A1m7Edcl4s2ZtDv6IrHjbiKKUvH1MVqysq6Li7McFeZbSjjEmBe-ekouy7YSsGrYiv2-tdRr0gcJoaAKL04EGS4HucZxgAZ8T9W5Bup0HGIs-LFmURoSUQpwg_8aQQRfnRM8r0asv3-Ub6ka6RfDT9kA321xOmEs2d6RrekNjFgyD-4XmLTVh7j0WvXdjfu09aOxDocM4xeA9GjpFB_45eWLBJ3xxzpfk293t183H4v7zh0-bm_tCi05MhSzLCritJWZj2saIivWNzTZIWXccasNQc9uJqgTWSKiAQQu9wcZKIwTU4pJcnebuY_g5Y5rU4JJG72HEMCfFu6qsm1byKqOv_0F3YY5j3u5ICZbJimdKnigdQ0oRrdpHN0A8KM7U8Zpqp87WqeM1FWtzHPtenafP_YDmb9ef82Xg_QnAbMfiMKqkHY4ajYuoJ2WC-4_EAwfEtO4</recordid><startdate>20171013</startdate><enddate>20171013</enddate><creator>Mo, Zhaojun</creator><creator>Mo, Yi</creator><creator>Li, Mingqiang</creator><creator>Tao, Junhui</creator><creator>Yang, Xu</creator><creator>Kong, Jilian</creator><creator>Wei, Dingkai</creator><creator>Fu, Botao</creator><creator>Liao, Xueyan</creator><creator>Chu, Jianli</creator><creator>Qiu, Yuanzheng</creator><creator>Hille, Darcy A.</creator><creator>Nelson, Micki</creator><creator>Kaplan, Susan S.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20171013</creationdate><title>Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial</title><author>Mo, Zhaojun ; Mo, Yi ; Li, Mingqiang ; Tao, Junhui ; Yang, Xu ; Kong, Jilian ; Wei, Dingkai ; Fu, Botao ; Liao, Xueyan ; Chu, Jianli ; Qiu, Yuanzheng ; Hille, Darcy A. ; Nelson, Micki ; Kaplan, Susan S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-5224a1f65e01787d340b7f41055691a6d0ec1f9342a075a4a0a8abde7f5d33a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age</topic><topic>Antigens</topic><topic>Diarrhea</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Double-blind studies</topic><topic>Effectiveness</topic><topic>Efficacy</topic><topic>Gastroenteritis</topic><topic>Guardians</topic><topic>Hospitalization</topic><topic>Immunization</topic><topic>Infants</topic><topic>Intussusception</topic><topic>Pediatrics</topic><topic>Randomization</topic><topic>Rotavirus</topic><topic>Rotavirus gastroenteritis</topic><topic>Rotavirus vaccine</topic><topic>Safety</topic><topic>Serotypes</topic><topic>Surveillance</topic><topic>Vaccination</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mo, Zhaojun</creatorcontrib><creatorcontrib>Mo, Yi</creatorcontrib><creatorcontrib>Li, Mingqiang</creatorcontrib><creatorcontrib>Tao, Junhui</creatorcontrib><creatorcontrib>Yang, Xu</creatorcontrib><creatorcontrib>Kong, Jilian</creatorcontrib><creatorcontrib>Wei, Dingkai</creatorcontrib><creatorcontrib>Fu, Botao</creatorcontrib><creatorcontrib>Liao, Xueyan</creatorcontrib><creatorcontrib>Chu, Jianli</creatorcontrib><creatorcontrib>Qiu, Yuanzheng</creatorcontrib><creatorcontrib>Hille, Darcy A.</creatorcontrib><creatorcontrib>Nelson, Micki</creatorcontrib><creatorcontrib>Kaplan, Susan S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mo, Zhaojun</au><au>Mo, Yi</au><au>Li, Mingqiang</au><au>Tao, Junhui</au><au>Yang, Xu</au><au>Kong, Jilian</au><au>Wei, Dingkai</au><au>Fu, Botao</au><au>Liao, Xueyan</au><au>Chu, Jianli</au><au>Qiu, Yuanzheng</au><au>Hille, Darcy A.</au><au>Nelson, Micki</au><au>Kaplan, Susan S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2017-10-13</date><risdate>2017</risdate><volume>35</volume><issue>43</issue><spage>5897</spage><epage>5904</epage><pages>5897-5904</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•A randomized, double-blind, placebo-controlled trial was conducted in healthy Chinese infants.•Efficacy and safety of a pentavalent rotavirus vaccine (RV5) were assessed.•Efficacy against rotavirus gastroenteritis of any-severity caused by any serotype was 69.3%.•Efficacy against severe rotavirus gastroenteritis caused by any serotype was 78.9%.•RV5 was efficacious and generally well-tolerated in Chinese infants.
A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE).
4040 participants aged 6–12weeks were enrolled and randomly assigned to either 3 oral doses of RV5 (n=2020) or placebo (n=2020), administered ∼4weeks apart. The participants also received OPV and DTaP in a concomitant or staggered fashion. The primary objective was to evaluate vaccine efficacy (VE) against naturally-occurring RVGE at least 14days following the third dose. Key secondary objectives included: VE against naturally-occurring severe RVGE and VE against severe and any-severity RVGE caused by rotavirus serotypes contained in the vaccine, occurring at least 14days after the third dose. All adverse events (AEs) were collected for 30days following each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. (ClinicalTrials.gov registry: NCT02062385).
VE against RVGE of any-severity caused by any serotype was 69.3% (95% CI: 54.5, 79.7). The secondary efficacy analysis showed an efficacy of: 78.9% (95% CI: 59.1, 90.1) against severe RVGE caused by any serotype; 69.9% (95% CI: 55.2, 80.3) and 78.9% (95% CI: 59.1, 90.1) against any-severity and severe RVGE caused by serotypes contained in the vaccine, respectively. Within 30days following any vaccination, 53.5% (1079/2015) and 53.3% (1077/2019) of participants reported at least one AE, and 5.8% (116/2015) and 5.7% (116/2019) reported SAEs in the vaccine and placebo groups, respectively. No SAEs were considered vaccine-related in recipients of RV5. Two intussusception cases were reported in recipients of RV5 who recovered after receiving treatment. Neither was considered vaccine-related.
In Chinese infants, RV5 was efficacious against any-severity and severe RVGE caused by any serotype and generally well-tolerated with respect to AEs.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>28935470</pmid><doi>10.1016/j.vaccine.2017.08.081</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2017-10, Vol.35 (43), p.5897-5904 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1942678514 |
| source | Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Age Antigens Diarrhea Disease control Disease prevention Double-blind studies Effectiveness Efficacy Gastroenteritis Guardians Hospitalization Immunization Infants Intussusception Pediatrics Randomization Rotavirus Rotavirus gastroenteritis Rotavirus vaccine Safety Serotypes Surveillance Vaccination Vaccine efficacy Vaccines Viruses |
| title | Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A59%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20a%20pentavalent%20live%20human-bovine%20reassortant%20rotavirus%20vaccine%20(RV5)%20in%20healthy%20Chinese%20infants:%20A%20randomized,%20double-blind,%20placebo-controlled%20trial&rft.jtitle=Vaccine&rft.au=Mo,%20Zhaojun&rft.date=2017-10-13&rft.volume=35&rft.issue=43&rft.spage=5897&rft.epage=5904&rft.pages=5897-5904&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2017.08.081&rft_dat=%3Cproquest_cross%3E1942678514%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1943094241&rft_id=info:pmid/28935470&rft_els_id=S0264410X17311817&rfr_iscdi=true |